Dalrada Financial Corp (OTCQB:DFCO) said due to the growing need for precision medicine, it is entering the global genomics market with the launch of its subsidiary Dalrada Health’s product portfolio, Empower Genomics.
The company said Empower is producing and providing a custom-labeled suite of tests, including pharmacogenomics (PGx) and testing analysis for alternative therapies such as nutraceuticals, nutrition/diet, and exercise/fitness.
READ: Dalrada Financial appoints new executive vice president of sales and business development
Testing a person’s genetic traits helps to better understand how their nervous system and body will react to different variants of medications, natural botanicals, and foods, Dalrada said, adding that Empower’s tests reveal food sensitivity and allergies, metabolic health factors, vitamin deficiencies, factors for fitness strength, recovery, performance, and more.
The company also said the product line complements Dalrada Health’s suite of products with common target markets, and a support system of technology and data analytics leveraging Prakat’s healthcare systems & engineering expertise. Technology & software will also play a major role in how Empower Genomics delivers its services effectively using a secure and confidential process, it said.
Dalrada also highlighted that the global genomics market size is projected to reach US$54.4 billion by 2025 from US$22.7 billion in 2020.
Contact the author at calum@proactiveinvestors.com
Follow him on Twitter @Cal_Proac